Targets › HGF
3 programs from 3 companies in 4 trials: 2 Phase 1, 2 Phase 3; Ophthalmology, Oncology, Respiratory; next expected readout Feb 2027.
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. (UniProt, P14210)
Open in Phaseline: the race on HGF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kringle Pharma | KP-100LI Recombinant human hepatocyte growth factor (HGF) | HGF | Phase 3 | Vocal Fold Scar | Feb 2027 |
| AVEO Pharmaceuticals | Ficlatuzumab (AV-299) Hepatocyte growth factor inhibitor | HGF | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma | Aug 2027 |
| Claris Biotherapeutics | CSB-001 Ophthalmic Solution 0.1% Human recombinant dHGF (5-amino acid deleted hepatocyte growth factor) | HGF | Phase 1 | Corneal Scar; Limbal Stem Cell Deficiency | Jun 2027 |
Corneal Scar (1) Limbal Stem Cell Deficiency (1) Metastatic Head-and-neck Squamous-cell Carcinoma (1) Vocal Fold Scar (1)
protein or peptide (1), antibody (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.